Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Nerve-Stimulation Therapy for Patients with Treatment-Resistant Depression Now Available in New York


Vagus Nerve Stimulation (VNS) Therapy Is the Only Implantable Device Specifically Indicated for Long-term Treatment of TRD

NewYork-Presbyterian Hospital/Columbia University Medical Center is the first in the greater New York City-area to offer Vagus Nerve Stimulation (VNS) Therapy as a long-term treatment specifically approved by the FDA for treatment-resistant depression (TRD).

VNS Therapy is approved as a long-term adjunctive (add-on) treatment for patients 18 years of age and older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. VNS Therapy was approved for the treatment of drug-resistant epilepsy in 1997, and is now the first treatment specifically studied and approved for TRD.

Major depressive disorder is one of the most prevalent and serious illnesses in the U.S., affecting nearly 19 million Americans every year. Of those, one fifth, or approximately four million people, do not respond to multiple antidepressant treatments. For these people, psychotherapy, antidepressant medications, and even sometimes electroconvulsive therapy do not work, or only work for a short while and stop working over time. VNS Therapy is a newly approved treatment option for these people.

“Patients with treatment-resistant depression need safe and effective therapeutic options. The availability of an FDA-approved treatment for the long-term management of depression is an important development for the disturbingly large number of people with depression who have not responded to other approved treatment options,” says Dr. Sarah H. Lisanby, director of the Columbia Brain Stimulation Service at NewYork-Presbyterian/Columbia University Medical Center and associate professor of clinical psychiatry at Columbia University College of Physicians and Surgeons. She is also director of the Brain Stimulation and Neuromodulation Division, director of the Brain Behavior Clinic, and research scientist in the Department of Neuroscience at the New York State Psychiatric Institute.

“Open studies suggest that the benefits from VNS were sustained over time, and that VNS was very tolerable with few side effects,” continues Dr. Lisanby.

Early clinical research of VNS Therapy for TRD was conducted at study sites, including NewYork-Presbyterian/Columbia, beginning in 2001. Recent studies have found that half of patients with an average of 25 years of major depressive disorder and multiple treatment trials realized some clinical benefit; one-third of patients had at least a 50 percent improvement in their depression; and one out of six was depression-free after treatment with VNS Therapy. Patients also reported significant improvements in quality-of-life areas, such as vitality, mental health, emotional well-being, and social functioning.

“VNS Therapy is delivered from a small pacemaker-like device implanted in the chest area that sends mild pulses to the brain via the vagus nerve in the neck. A thin, insulated wire, attached to the generator, runs under the skin to the left vagus nerve,” says Dr. Guy M. McKhann II, Florence Irving Assistant Professor of Neurological Surgery at Columbia University College of Physicians and Surgeons and assistant attending neurosurgeon at NewYork-Presbyterian/Columbia University Medical Center. The vagus nerve, one of the 12 cranial nerves, serves as the body’s “information highway” connecting the brain to many major organs. Several studies have shown that VNS Therapy may modulate neurotransmitters such as serotonin and norepinephrine thought to be involved in mood regulation.

Cyberonics, Inc., of Houston, manufactures the VNS Therapy System™.

For more information, interested patients may call (212) 543-5558 or email

Craig LeMoult | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

How nanoscience will improve our health and lives in the coming years

27.10.2016 | Materials Sciences

OU-led team discovers rare, newborn tri-star system using ALMA

27.10.2016 | Physics and Astronomy

'Neighbor maps' reveal the genome's 3-D shape

27.10.2016 | Life Sciences

More VideoLinks >>>